Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-10500259-B2
Application number	US-201715849878-A
Country	US
Kind code	B2
Filing date	Dec 21, 2017
Priority date	Aug 5, 2015
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cells which present a peptide consisting of the amino acid sequence of HLLEDIAHV (SEQ ID NO: 3),
wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MEW molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells;
wherein said cancer is selected from the group consisting of liver cancer, breast cancer, uterine cancer, gallbladder cancer, bile duct cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, and esophageal cancer.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the MHC molecule is a class I MHC molecule.

7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

9. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

10. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

11. The method of claim 1 , wherein the contacting T cells is in vitro.

12. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

13. The method of claim 12 , wherein the composition comprises an adjuvant.

14. The method of claim 13 , wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations, with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

15. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of HLLEDIAHV (SEQ ID NO: 3).

16. The method of claim 15 , wherein the immune response comprises a cytotoxic T cell response.

17. The method of claim 1 , wherein the cancer is liver cancer.

18. The method of claim 1 , wherein the cancer is breast cancer.

19. The method of claim 1 , wherein the cancer is uterine cancer.

20. The method of claim 1 , wherein the cancer is ovarian cancer.

Assignees

• immatics biotechnology GmbH
• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/158

  Expression markers · CPC title